Marengere, Luc (TVM 201308 Managing Partner) |
Managing Partner |
TVM (Group) |
Germany |
Marescaux, Jacques (IRCAD Strasbourg 202409 President + Founder) |
President/Director/Head Business Group/Unit/Division |
IRCAD Strasbourg (Institute for Research against Cancer of the Digestive System) |
France |
Marett, Sean (BioNTech 202012–202406 CBO + CCO 201506 COO before Evotec RETIRED 6/24 continuing as advisor) |
Chief Operating Officer (COO) |
BioNTech (Group) |
Germany |
Margeson, Kristen (Atlas Venture 201601 Director IR + Marketing) |
Public Relations Manager / Investor Relations Manager |
Atlas Venture (Group) |
United States (USA) |
Margraf, Iris (Coral BioNet 201102 Director Business Development at Scil Technology GmbH) |
Business Development Manager / Strategy Manager |
Coral BioNet (Group) |
Germany |
Marguerre, Wolfgang (Octapharma 201209 Chairman + Founder) |
Board member |
Octapharma (Group) |
Switzerland |
Mariën, Rudi (Innogenetics 2007 Chairman + major owner) |
Venture Partner |
Biovest N.V. (Belgium, Rudi Mariën) |
Belgium |
Mariggi, Giovanni (Medicxi 202208 Partner) |
Partner (venture partner) |
Medicxi Ventures (formerly Index Ventures Life Sciences) |
United Kingdom (GB) |
Marini, Davide (Firefly BioWorks 201310 CEO) |
Chief Executive Officer (CEO) |
Firefly BioWorks Inc. |
United States (USA) |
Marini, Luca (Xyence Capital 202205 CEO) |
Chief Executive Officer (CEO) |
Xyence Capital SGR |
Italy |
Marino, Daniela (Cutiss 202006 CEO + Co-Founder) |
Chief Executive Officer (CEO) |
Cutiss AG |
Switzerland |
Marinucci, Francesco (Partec 201212 Director of Partec Essential Healthcare division) |
President/Director/Head Business Group/Unit/Division |
Sysmex (Group) |
Germany |
Mark, Antje (JeNaCell GmbH 201507 Marketing Manager) |
Sales Manager / Marketing Manager |
JeNaCell GmbH |
Germany |
Mark, Daniel L. (SpinDiag GmbH 201707 Managing Director) |
Managing Director |
Spindiag GmbH |
Germany |
Markfort, Rainer (Dentons 201501– Partner before Mayer Brown Düsseldorf + White & Case Berlin) |
Attorney / Lawyer |
Dentons (Group) |
Switzerland |
Markó, Kornél G. (Averbis GmbH 2007– Managing Director + Co-Founder) |
Managing Director |
Acus Laboratories GmbH |
Germany |
Markovic, Sandra (LeadXPro 201804 Discovery Project Leader) |
Research & Development Manager |
LeadXPro AG |
Switzerland |
Marks, Daniel (RA Capital 202204 Principal) |
Principal (venture capital) |
RA Capital Management L.P. |
United States (USA) |
Marks, Eric (BRAIN 201511–201610 COO before AB Enzymes 2006–2015 RESIGNED 10/16) |
Chief Operating Officer (COO) |
BRAIN Biotech (Group) |
Germany |
Marks, Ian (Salesforce 202108 VP Life Sciences before GSK + Novartis) |
President/Director/Head Business Group/Unit/Division |
Salesforce.com Inc. (NYSE: CRM) |
United States (USA) |
Marlière, Philippe (Global Bioenergies 201702 Partner + Co-Founder) |
Company Founder |
Global Bioenergies (Group) |
France |
Marotta, Marco (Relief Therapeutics 202111– promoted to CBO joined with acquisition of APR Applied Pharma Research) |
Business Development Manager / Strategy Manager |
Relief Therapeutics (Group) |
Switzerland |
Marquart, Maximilian (Max) (Planet A Foods 202402 Managing Director + Co-Founder) |
Managing Director |
Planet A Foods GmbH (ChoVIva) |
Germany |
Marquart, Sara F. (Planet A Foods 202402 Managing Director + Co-Founder) |
Managing Director |
Planet A Foods GmbH (ChoVIva) |
Germany |
Marriott, Peter (SGS 201012 Global Technical & Accreditation Manager) |
Technical Manager |
SGS (Group) |
Switzerland |
Marron, Damian (Agalimmune 201603 CEO before TxCell + Cytheris + Trophos + NiCox + 3M + Orphan Europe) |
Chief Executive Officer (CEO) |
BioLineRx (Group) |
United Kingdom (GB) |
Marsat, Jean-Luc (EverImmune 202111 CEO formerly SGS 201611 Managing Director at SGS Clinical Research) |
Chief Executive Officer (CEO) |
EverImmune (FR) |
France |
Marschner, Jens-Peter (Zelluna 201906– CMO before AbbVie + Affimed + Merck KGaA + Bayer + Boehringer Mannheim) |
Chief Medical Officer (CMO) |
Affimed (Group) |
Germany |
Marseille, Oliver (Hemovent GmbH 201602 Managing Director (CTO) + Co-Founder) |
Managing Director |
Hemovent GmbH |
Germany |
Marshak, Daniel R. (PerkinElmer 200807 CSO President China) |
Chief Scientific Officer (CSO) / Chief Development Officer (CDO) |
PerkinElmer (Group) |
United States (USA) |
Marshak, Daniel R. (Tecan 201710– Board proposed before PerkinElmer + Cambrex) |
Board member, non-executive |
Tecan (Group) |
Switzerland |
Marshall, Alan G. (Florida State Univ 201003 Professor + National High Magnetic Field Labaoratory Director ICR Program) |
Professor |
Florida State University (FSU) |
United States (USA) |
Marshall, Fiona H. (Novartis 202211– President of NIBR before Merck + Heptares + Millennium Pharma + GSK) |
President/Director/Head Business Group/Unit/Division |
Novartis (Group) |
Switzerland |
Marston, Hugh (Boehringer 202403 Global Head CNS Discovery Research) |
Research & Development Manager |
Boehringer Ingelheim (Group) |
Germany |
Martello, Wan Ling (Nestlé 201402 CFO) |
Chief Financial Officer (CFO) |
Nestlé (Group) |
Switzerland |
Martens, Hubert (Salvia BioElectronics 202009 CEO + Founder) |
Chief Executive Officer (CEO) |
Salvia BioElectronics B.V. |
Netherlands |
Martens, Lejon (A & M Labor für Analytik 201009 Head Mass Spec Lab) |
Head Mass Spectrometry / NMR Laboratory (industry) |
A&M Labor für Analytik (Group) |
Germany |
Martens, Tom (UgenTec NV 201712 Managing Director) |
Managing Director |
UgenTec N.V. |
Belgium |
Martí, Laura (Reig Jofré 202312– CFO before Audax Renovables + General Electric) |
Chief Financial Officer (CFO) |
Reig Jofré (Group) |
Spain (España) |
Martin, Alex (Affectis 201003–CEO before CFO before Intercept before BioXell 200606 CFO before Novartis) |
Chief Executive Officer (CEO) |
Affectis Pharmaceuticals AG |
Germany |
Martin, Chris (Auven Therapeutics 201506 CEO of ADC Therapeutics before CEO of Spirogen Ltd) |
Managing Director |
ADC Therapeutics (Group) |
Switzerland |
Martin, Fred (Subject Well 202409 CEO) |
Chief Executive Officer (CEO) |
Subject Well (SubjectWell) (Group) |
United States (USA) |
Martin, Gilles G. (Eurofins 200701 CEO + founder) |
Chief Executive Officer (CEO) |
Eurofins (Group) |
France |
Martin, Jacques-François (Parteurop Pharma 201602 President + Founder before Mymetics + Chiron Vaccines) |
Chief Executive Officer (CEO) |
Parteurop Pharma (FR) |
France |
Martin, Javier (Genycell Biotech 201107 CEO) |
Chief Executive Officer (CEO) |
Genycell Biotech España S.L. |
Spain (España) |
Martin, Keith (Apitope 201810 Non-Executive Director before 2006–201810 CEO RETIRED 10/18) |
Board member, non-executive |
Apitope (Group) |
United Kingdom (GB) |
Martin, Kelly (Malin Corp 201508– CEO before Elan CEO) |
Chief Executive Officer (CEO) |
Élan (Group) |
Ireland, Republic of |
Martin, Klaus (Topas Therapeutics 202008– CEO before Apobiologix + Polpharma Biologics + Sandoz Biopharmaceuticals) |
Chief Executive Officer (CEO) |
Topas Therapeutics GmbH |
Germany |
Martin, Kurt (Hepacult 201104 Managing Director) |
Managing Director |
Hepacult GmbH |
Germany |
Martin, Roland (Univ Zürich 201104– Professor + Head Dept Neuroimmunology at Univ Hospital Zürich before inims Hamburg) |
Professor |
University of Zurich (UZH) |
Switzerland |
Martin-Garcia, Jesús (Eclosion 201207 General Partner + Founder + GeNeuro 201512 CEO) |
General Partner (venture partner) |
Eclosion S.A. |
Switzerland |
Martínez, Héctor (Cellink 201908202403 CTO + Co-Founder LEFT 3/24) |
Chief Technology/Technical Officer (CTO) |
Bico (Group) |
Sweden |
Martinez, Ignacio (Flagship Pioneering 201303– General Partner formerly Syngenta Ventures) |
Investment Manager |
Flagship Pioneering |
United States (USA) |
Martinez-Davis, Maya (GSK 202001– President of GSK US Pharma joined 9/19 before Merck (DE) + Pfizer) |
President/Director/Head Business Group/Unit/Division |
GSK (Group) |
United Kingdom (GB) |
Martins, Fabien (MFPL 201107 Managing Director) |
Managing Director |
Max F. Perutz Laboratories GmbH (MFPL) |
Austria |
Martis, Remberto (LenioBio 202203 Managing Director (CEO) + Founder) |
Managing Director |
LenioBio GmbH |
Germany |
Martorana, Domenica (Qiagen 202409 Associate Director Global Investor Relations) |
Public Relations Manager / Investor Relations Manager |
Qiagen (Group) |
Germany |
Martyr, David (Tecan 201202–201903 announced CEO for 10/12 before Leica Microsystems RETIRED 4/19) |
Chief Executive Officer (CEO) |
Tecan (Group) |
Switzerland |
Maruyama, Hisashi (Hitachi 201901 CEO of Hitachi Chemical Co. Ltd.) |
Chief Executive Officer (CEO) |
Resonac (Group) |
Japan |
Marx, Thomas (RheinCell Therapeutics 202106 Chief Commercial Officer joined 2019) |
Business Development Manager / Strategy Manager |
Catalent (Group) |
Germany |
Marx, Uwe (TissUse GmbH 201002– Managing Director + TU Berlin 201004– before ProBioGen –200411 CSO) |
Chief Executive Officer (CEO) |
TissUse GmbH |
|
Maschek, Uwe (MagForce 200705–200912 CEO resigned 12/09 before Cephalon GmbH 1997–2007 Managing Director) |
Chief Executive Officer (CEO) |
MagForce (Group) |
Germany |
Mascher, Hermann (pharm-analyt 201202 CEO + founder) |
Chief Executive Officer (CEO) |
pharm-analyt Labor GmbH |
Austria |
Maskos, Michael (Institut für Mikrotechnik Mainz GmbH 201109– Managing Director) |
Managing Director |
Fraunhofer (Group) |
Germany |
Mason, Christopher E. (Cornell Univ 201606 Assoc Prof Institute for Computational Biomedicine at Weill Cornell Medicine) |
Professor |
Cornell University |
United States (USA) |
Mason, Mike (Eli Lilly 202001– President of Lilly Diabets before SVP Lilly Connected Care + Insulins) |
President/Director/Head Business Group/Unit/Division |
Eli Lilly (Group) |
United States (USA) |
Mason, Richard (Apollo Therapeutics 202401 CEO formerly JnJ Innovation Centre London +XO1 + BTG + 4-Antibody) |
President/Director/Head Business Group/Unit/Division |
Apollo Therapeutics (Group) |
United Kingdom (GB) |
Mason, William T. (Bill) (The Sage Group 201503 Head of Sage Europe) |
Consultant (economic/technology) |
Sage Group (Group) |
United Kingdom (GB) |
Massari, Nate (Anjarium Biosciences 202207– CBO before Aytu BioPharma + Rumpus Therapeutics + JnJ + Endo Pharma) |
Chief Business Officer (CBO) |
Anjarium Biosciences AG |
Switzerland |
Massera, Patricio (Asahi Glass 202108 CEO of AGC Biologics) |
Chief Executive Officer (CEO) |
Asahi Glass (AGC) (Group) |
United States (USA) |
Massey, Ian (Synosis 200701– CEO before Roche Bioscience) |
Chief Executive Officer (CEO) |
Acorda Therapeutics (Group) |
United States (USA) |
Massner, Christoph (Earlybird 202004 Early-stage VC Investor in Healthcare) |
Investment Manager |
Earlybird (Group) |
Germany |
Massouras, Andreas (Saphetor SA 201604 CEO + Founder before Citigroup + Credit Suisse + Salomon Brothers) |
Chief Executive Officer (CEO) |
Saphetor S.A. (VarSome) |
Switzerland |
Massuyeau, Laurent (Addex 200804–200909 Head Business Developm before Idenix RESIGNED 9/09 at Addex) |
Business Development Manager / Strategy Manager |
Addex (Group) |
Switzerland |
Matchett, Geraldine (DSM 2022205 Co-CEO 201508 CFO) |
Chief Executive Officer (CEO) |
DSM (Group) |
Netherlands |
Máté, Veronika (Trophic Communications 202305) |
Public Relations Manager / Investor Relations Manager |
Trophic Communications GmbH |
Germany |
Matentzoglu, Konstantin (Celonic 201711 CEO before Trenzyme GmbH 201202 Managing Director) |
Managing Director |
Celonic (Group) |
Switzerland |
Mateus, Manel (Optimum Strategic Communications 201902) |
Public Relations Manager / Investor Relations Manager |
Optimum Strategic Communications |
United Kingdom (GB) |
Matheis, Georg (Stimit AG 202104 Board Director) |
Board member, non-executive |
Dräger (Group) |
Switzerland |
Mather, Simon (WestLB 200809 Analyst) |
Analyst (Financial / Industry) |
Portigon (Group) |
Germany |
Mathers, Edward T. (Ed) (New Enterprise Associates 200808– before MedImmune) |
Partner (venture partner) |
New Enterprise Associates (NEA) |
United States (USA) |
Mathew, Prasad (Bayer 201207 VP Global Medical Affairs Hematology at Bayer HealthCare) |
n. a. |
Bayer (Group) |
Germany |
Mathias, Frank (Oxford Biomedica 202203– CEO before Rentschler + Medigene + Amgen GmbH + Servier DE + Hoechst) |
Managing Director |
Oxford Biomedica (Group) |
United Kingdom (GB) |
Mathis, Luc (Meiogenix 202112 CEO before Global Bioenergies + Calyxt + Cellectis Plant Sciences) |
Chief Business Officer (CBO) |
Meiogenix SAS |
France |
Mathisen, Svein (BioInvent 200510 CEO) |
Chief Executive Officer (CEO) |
BioInvent International AB (Nasdaq Stockholm: BINV) |
Sweden |
Mathur, Supriya (Optimum Strategic Communications 201905 before Hume Brophy) |
Public Relations Manager / Investor Relations Manager |
Optimum Strategic Communications |
United Kingdom (GB) |
Matillon, Valentin (Sophia Genetics 201801– CFO before Hobart Group + SITA + Electronic Arts + Hewlett-Packard Europe) |
Chief Financial Officer (CFO) |
Sophia Genetics (Group) |
Switzerland |
Matis, Louis A. (Pieris 201508– Chief Development Officer before Alexion + CGI Pharmaceuticals) |
Chief Medical Officer (CMO) |
Palvella Therapeutics (Group) |
United States (USA) |
Matlow, Stuart (Stu) (Thermo Fisher 201206 Public Relations Manager Chromatography + Mass Spectrometry before Agilent) |
Public Relations Manager / Investor Relations Manager |
Thermo Fisher (Group) |
United States (USA) |
Matsumoto, Hiroshi (RIKEN 201910 President) |
President/Director/Head Business Group/Unit/Division |
RIKEN Research Cluster for Innovation (JP) |
Japan |
Matsumoto, Yuiko (Takara Shuzo 202308 Product Manager at Takara Bio USA) |
Product Manager (personnel) |
Takara Shuzo (Group) |
United States (USA) |
Mattacchione, Anthony L. (Tony) (Albany Molecular 201804– before Bruker Corp CFO + EMD Millipore) |
Chief Financial Officer (CFO) |
Curia (Group) |
United States (USA) |
Mattaj, Iain (EMBL 200811 Director General) |
President/Director/Head Business Group/Unit/Division |
EMBL (European Molecular Biology Laboratory) |
Germany |
Matter, Alex (Singapore (govt) 201310 CEO ETC of A*STAR before Novartis Global Head Oncology Research) |
Chief Executive Officer (CEO) |
Singapore (govt) |
Singapore |
Mattessich, Antony (Purdue Pharma 201612 Managing Director of Mundipharma International Ltd) |
Managing Director |
Purdue Pharma (Group) |
United Kingdom (GB) |
Matthes, Thomas (Sloning 200705– CBO before Sigma-Aldrich SAFC Biosciences before CellSystems Biotechnologie GmbH) |
Chief Business Officer (CBO) |
Novartis (Group) |
Germany |
Matthews, Keith, Chief (ICIF 202203 Chairman) |
Board member |
Indigenous Critical Infrastructure Fund Canada (ICIF) |
Canada |
Matthews, Werner |
n. a. |
Sparkassen-Finanzgruppe (DE) [FICTIVE UNIT, NOT OFFICIAL GROUP!] (Group) |
Germany |
Matthyssens, Gaston (Vesalius Biocapital 201006 Investment Manager) |
Managing Partner (investment firm) |
Vesalius Biocapital (Group) |
Luxembourg |
Mattil, Evi (Cryo-Save 201302– Chief Commercial Officer before Amoena + IMS Health (DE) + Chiron Vaccines) |
Chief Commercial Officer (CCO) |
Cryo-Save AG (CH) |
Switzerland |